Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Whitehawk Therapeutics (Nasdaq: WHWK), an oncology therapeutics company focused on ADC cancer treatments, has announced its upcoming participation in two major investor conferences. CEO Dave Lennon will engage in fireside chats at the Morgan Stanley Global Healthcare Conference on September 8, 2025 at 4:50 PM ET and the H.C. Wainwright Global Investment Conference on September 9, 2025 at 3:30 PM ET.

Both events will be held in New York City and will feature live webcasts accessible through Whitehawk's IR website, with replays available for approximately 30 days after the events.

News Market Reaction – WHWK

+0.83%

+0.83% Session close to close

In the Sep 2 session, WHWK gained 0.83%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY:

• Morgan Stanley 23^rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.
  
  
• H.C. Wainwright 27^th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.

A live webcast of the fireside chat events can be accessed by visiting the Whitehawk Therapeutics IR website. These will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics 
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact
IR@whitehawktx.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302543271.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

When is Whitehawk Therapeutics (WHWK) presenting at the Morgan Stanley Healthcare Conference 2025?

Whitehawk Therapeutics' CEO Dave Lennon will participate in a fireside chat at the Morgan Stanley Conference on September 8, 2025 at 4:50 PM ET in New York City.

How can investors access Whitehawk Therapeutics' (WHWK) conference presentations?

Investors can access the live webcasts of both fireside chats through Whitehawk Therapeutics' IR website. Replays will be available for approximately 30 days after the events.

What conferences is Whitehawk Therapeutics (WHWK) attending in September 2025?

Whitehawk Therapeutics is attending the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025.

Who will represent Whitehawk Therapeutics (WHWK) at the upcoming investor conferences?

Dave Lennon, PhD, the president and CEO of Whitehawk Therapeutics, will represent the company at both conferences.